1. Etzioni A, Ochs HD. The hyper IgM syndrome— an evolving story. Pediatric research. 2004;56(4):519. 2. Leven EA, Maffucci P, Ochs HD, Scholl PR, Buckley RH, Fuleihan RL, et al. Hyper IgM syndrome: a report from the USIDNET registry. Journal of clinical immunology. 2016;36(5):490- 501. 3. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259(5097):990-3. 4. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyperIgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373-84. 5. Delbari MT, Cheraghi T, Yazdani R, Fekrvand S, Delavari S, Azizi G, et al. Clinical Manifestations, Immunological Characteristics and Genetic Analysis of Patients with Hyper-Immunoglobulin M Syndrome in Iran. International archives of allergy and immunology. 2019:1-12. 6. Hollenbaugh D, Grosmaire L, Kullas C, Chalupny NJ, Braesch‐Andersen S, Noelle R, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐ stimulatory activity. The EMBO journal. 1992;11(12):4313-21. 7. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proceedings of the National Academy of Sciences. 1992;89(14):6550-4. 8. Miga A, Masters S, Gonzalez M, Noelle R. The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunological investigations. 2000;29(2):111-4. 9. Noelle RJ. CD40 and its ligand in host defense. Immunity. 1996;4(5):415-9. 10. Tsai H-Y, Yu H-H, Chien Y-H, Chu K-H, Lau Y-L, Lee J-H, et al. X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients. Journal of Microbiology, Immunology and Infection. 2015;48(1):113-8. 11. Yazdani R, Fekrvand S, Shahkarami S, Azizi G, Moazzami B, Abolhassani H, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clinical Immunology. 2018.12. Qamar N, Fuleihan RL. The hyper IgM syndroms Clinical reviews in allergy & immunology. 2014:46 (2):120-30. 13. Chavoshzadeh Z, Mahdaviani SA, Momen T, et al. Fourth Update on the Iranian National Registry of Primary Immunodeficiencies: Integration of Molecular Diagnosis. Journal of clinical immunology. 2018;38(7):816-32. 14. Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. Journal of clinical immunology. 2014;34(4):478-90. 15. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research. 1988;16(3):1215. 16. Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. Journal of Allergy and Clinical Immunology. 2018;141(4):1450-8. 17. Abolhassani H, Aghamohammadi A, Fang M, Rezaei N, Jiang C, Liu X, et al. Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency. Genetics in Medicine. 2019;21(1):243. 18. Tang WJ, An YF, Dai RX, Wang QH, Jiang LP, Tang XM, et al. Clinical, molecular, and T cell subset analyses in a small cohort of Chinese patients with hyper-IgM syndrome type 1. Human immunology. 2014;75(7):633-40. 19. Ouadani H, Ben-Mustapha I, Ben-ali M, Benkhemis L, Largueche B, Boussoffara R, et al. Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients. Immunogenetics. 2016;68(1):19-28. 20. Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of Xlinked hyper-IgM syndrome. The Journal of pediatrics. 1997;131(1 Pt 1):47-54. 21. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyperIgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373-84. 22. Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. British journal of haematology. 2010;149(2):167-80. 23. Hirbod-Mobarakeh A, Aghamohammadi A, Rezaei N. Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again. Expert review of clinical immunology. 2014;10(1):91-105. 24. Mavroudi I, Papadaki V, Pyrovolaki K, Katonis P, Eliopoulos AG, Papadaki HA. The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis. Journal of leukocyte biology. 2011;89(5):771-83. 25. Rawat A, Mathew B, Pandiarajan V, Jindal A, Sharma M, Suri D, et al. Clinical and molecular features of X-linked hyper IgM syndrome-An experience from North India. Clinical immunology (Orlando, Fla). 2018;195:59-66.